Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion

British Journal of Pharmacology

Volumn 121, Issue 4, 1997, Pages 799-805

  Mourtada, Mirna ^a   Brown, Colin A ^a   Smith, Stephen A ^b   Piercy, Valerie ^b   Chan, Susan L F ^a   Morgan, Noel G ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti hyperglycaemic drugs; Diabetes mellitus; Efaroxan; Endocrine pancreas; Glibenclamide; Pancreatic cell

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; EFAROXAN; GLIBENCLAMIDE; GLUCOSE; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE RECEPTOR; INSULIN; PERTUSSIS TOXIN; PHENOXYBENZAMINE; SULFONYLUREA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; STEREOCHEMISTRY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BENZOFURANS; DRUG INTERACTIONS; GLYBURIDE; HYPOGLYCEMIC AGENTS; IDAZOXAN; IMIDAZOLES; INSULIN; ISLETS OF LANGERHANS; MALE; RATS; RATS, WISTAR; STEREOISOMERISM;

EID: 0030925097     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701172     Document Type: Article

References (25)

1. BERDEU, D., GROSS, R., PUECH, R., LOUBATIERES-MARIANI, M.M. & BERTRAND, G. (1995). Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur. J. Pharmacol., 275, 91-98.
2. BERLIN, I., ROSENZWEIG, P., CHALON, S., FUSEAU, E., LANDAULT, C., CESSELIN, F., BLACKER, C. & PUECH, A.J. (1994). Reduction of hyperglycemia after oral glucose load by the new α2-adrenergic receptor antagonist SL84.0418 in healthy subjects. Clin. Pharmacol. Ther., 55, 338-345.
3. BERRIDGE, T.L., DOXEY, J.C. & ROACH, A.G. (1992). Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats. Eur. J. Pharmacol., 213, 213-218.
4. BROADSTONE, V.L., PFEIFER, M.A., BAJAJ, V., STAGNER, J.I. & SAMOLS. E. (1987). α-Adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes, 36, 932-937.
5. BROWN, C.A., CHAN, S.L.F., STILLINGS, M.R., SMITH, S.A. & MORGAN, N.G. (1993a). Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline RX801080. Br. J. Pharmacol., 110, 1017-1022.
6. BROWN, C.A., LOWETH, A.C., SMITH, S.A. & MORGAN, N.G. (1993b). Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. Br. J. Pharmacol., 108, 312-317.
7. 2-adrenoceptors and imidazoline-binding sites in the control of insulin secretion. Clin. Sci., 85, 671-677.
8. 2-adrenoceptor antagonist efaroxan is mediated by a novel; stereoselective, binding site. Eur. J. Pharmacol., 230, 375-378.
9. CHAN, S.L.F. & MORGAN, N.G. (1990). Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur. J. Pharmacol., 176, 97-101.
10. CHERKSEY, B. & ALTSZULER, N. (1984). Tolbutamide and glyburide differ in effectiveness to displace α- and β-adrenergic radioligands in pancreatic islet cells and membranes. Diabetes, 33, 499-503.
11. DUNNE, M.J. (1991). Block of ATP-regulated potassium channels by phentolamine and other α-adrenoceptor antagonists. Br. J. Pharmacol., 103, 1847-1850.
12. GARRINO, M.G. & HENQUIN, J.-C. (1990). B cell adrenoceptors and sulphonylurea-induced insulin release in mouse islets. Diabetologia, 33, 145-147.
13. GEY, G.O. & GEY, M.K. (1936). Maintenance of human normal cells in continuous culture: preliminary report; cultivation of mesoblastic tumors and normal cells and notes on methods of cultivation. Am. J. Cancer, 27, 45-76.
14. HENQUIN, J.-C. (1992). The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work? Diabetologia, 35, 907-912.
15. + channels in pancreatic β-cells. Br. J. Pharmacol., 107, 8-14.
16. KAWAZU, S., SUZUKI, M., WATANABE, T. & ISHII, J. (1987). Studies of midaglizole (DG-5128): a new type of oral hypoglycemic drug in healthy subjects. Diabetes, 36, 216-220.
17. MORGAN, N.G., CHAN, S.L.F., BROWN, C.A. & TSOLI, E. (1995). Characterization of the imidazoline binding site involved in regulation of insulin secretion. Ann. N.Y. Acad. Sci., 763, 361-373.
18. + channels in pancreatic B-cells. Exp. Clin. Endocrinol., 103, 42-45.
19. SATIN, L.S. (1996). New mechanisms for sulfonylurea control of insulin secretion. Endocrine, 4, 191-198.
20. SCHULZ, A. & HASSELBLATT, A. (1989). An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 340, 321-327.
21. SCHUTZ, W. & FREISSMUTH, M. (1992). Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol. Sci., 13, 376-380.
22. SIREK, A., SIREK, O.V. & POLICOVA, Z. (1974). Dihydroergotamine: a potent biological amplifier of sulphonylureas. Diabetologia, 10, 267-270.
23. 2-adrenoceptor antagonists. J. Med. Chem., 28, 1054-1062.
24. WANG, X., RONDU, F., LAMOURI, A., DOKHAN, R., MARC, S., TOUBOUL, E., PFEIFFER, B., MANECHEZ, D., RENARD, P., GUARDIOLA-LEMAITRE, B., GODFROID, J.-J., KTORZA, A. & PENICAUD, L. (1996). Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J. Pharmacol. Exp. Ther., 278, 82-89.
25. ATP channels and interaction with the exocytotic machinery. Diabetes, 45, 1610-1618.